AEMD vs. NEPH, RVP, NXGL, QTI, PTHL, IRIX, XAIR, LFWD, VVOS, and NRXS
Should you be buying Aethlon Medical stock or one of its competitors? The main competitors of Aethlon Medical include Nephros (NEPH), Retractable Technologies (RVP), NEXGEL (NXGL), QT Imaging (QTI), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), IRIDEX (IRIX), Beyond Air (XAIR), ReWalk Robotics (LFWD), Vivos Therapeutics (VVOS), and NeurAxis (NRXS). These companies are all part of the "medical equipment" industry.
Aethlon Medical vs.
Nephros (NASDAQ:NEPH) and Aethlon Medical (NASDAQ:AEMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk, institutional ownership and community ranking.
Nephros has higher revenue and earnings than Aethlon Medical. Nephros is trading at a lower price-to-earnings ratio than Aethlon Medical, indicating that it is currently the more affordable of the two stocks.
Nephros has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Aethlon Medical has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.
41.1% of Nephros shares are owned by institutional investors. Comparatively, 2.0% of Aethlon Medical shares are owned by institutional investors. 4.1% of Nephros shares are owned by company insiders. Comparatively, 1.1% of Aethlon Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Nephros had 1 more articles in the media than Aethlon Medical. MarketBeat recorded 5 mentions for Nephros and 4 mentions for Aethlon Medical. Aethlon Medical's average media sentiment score of 0.84 beat Nephros' score of 0.63 indicating that Aethlon Medical is being referred to more favorably in the news media.
Aethlon Medical has a net margin of 0.00% compared to Nephros' net margin of -6.86%. Nephros' return on equity of -11.39% beat Aethlon Medical's return on equity.
Nephros presently has a consensus target price of $5.00, suggesting a potential upside of 150.00%. Aethlon Medical has a consensus target price of $7.00, suggesting a potential upside of 1,737.27%. Given Aethlon Medical's higher possible upside, analysts clearly believe Aethlon Medical is more favorable than Nephros.
Aethlon Medical received 208 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 50.46% of users gave Aethlon Medical an outperform vote while only 43.33% of users gave Nephros an outperform vote.
Summary
Nephros and Aethlon Medical tied by winning 8 of the 16 factors compared between the two stocks.
Get Aethlon Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aethlon Medical Competitors List
Related Companies and Tools
This page (NASDAQ:AEMD) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy AEMD Stock Free AEMD Stock Alerts